Consegna Pharma is focused on developing long-acting injectable (LAI) drug products that aim to enhance therapeutic outcomes and economic value in various medical contexts. Their lead product, CP216, is a long-acting formulation of naloxone designed to address the critical issue of opioid overdose. By extending the release of naloxone over a period of 12-24 hours, CP216 aims to mitigate the risk of renarcotization, a phenomenon where patients may experience a secondary overdose due to the rapid metabolism of naloxone compared to synthetic opioids like fentanyl. This innovative approach not only addresses the urgent need for effective overdose reversal solutions but also highlights Consegna's commitment to improving patient adherence and drug delivery.

The company employs advanced technologies, including their proprietary Computational Drug Delivery™ software, known as ADSR™, which utilizes artificial intelligence to optimize drug formulation. This software analyzes various factors such as the active ingredient, excipients, desired release performance, and the specific environment in which the drug will be administered. By streamlining the formulation process, ADSR™ significantly reduces both the time and costs associated with drug development while also minimizing risks during clinical trials and manufacturing scale-up. This technological framework positions Consegna Pharma at the forefront of pharmaceutical innovation, particularly in the realm of long-acting medications.

United States

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

Consegna Pharma

Company Details